The use of solvent/detergent treatment in pathogen reduction of plasma

Transfusion Medicine and Hemotherapy

Volumn 38, Issue 1, 2011, Pages 65-70

  Hellstern, Peter ^a   Solheim, Bjarte G ^b  

^a KLINIKUM LUDWIGSHAFEN   (Germany)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Allergic reactions; Clinical efficacy; Pathogen inactivation; Solvent detergent treated plasma; Tolerance; Transfusion associated acute lung injury

Indexed keywords

BLOOD CLOTTING FACTOR 8; DETERGENT; FRESH FROZEN PLASMA; LEUKOCYTE ANTIBODY; PLASMA PROTEIN; PLASMIN INHIBITOR; PRION PROTEIN; SOLVENT;

ALLERGIC REACTION; ARTICLE; BLOOD CLOTTING; CLINICAL ASSESSMENT; CLINICAL STUDY; DILUTION; HEPATITIS A VIRUS; HUMAN PARVOVIRUS B19; MATERIALS; MICROBIOLOGICAL PHENOMENA AND FUNCTIONS; PATHOGEN REDUCTION; PLASMA; PROCESS DEVELOPMENT; PROTEIN FUNCTION; RESEARCH; SOLVENT DETERGENT TREATED PLASMA; TECHNOLOGY; TRANSFUSION RELATED ACUTE LUNG INJURY; VIRUS ENVELOPE; VIRUS INACTIVATION; VIRUS LOAD;

EID: 79851482225     PISSN: 16603796     EISSN: None     Source Type: Journal    
DOI: 10.1159/000323552     Document Type: Article

References (40)

1. Prince AM, Horowitz B, Brotman B: Sterilization of hepatitis and HTLV-III viruses by exposure to tri(n-butyl)phosphate and sodium cholate. Lancet 1986;i:706-710.
2. Dichtelmüller HO, Biesert L, Fabbrizzi F, Gajardo R, Gröner A, von Hoegen I, Jorquera JI, Kempf C, Kreil TR, Pifat D, Osheroff W, Poelsler G: Robustness of solvent/detergent treatment of plasma derivatives: a data collection from Plasma Protein Therapeutics Association member companies. Transfusion 2009;49:1931-1943.
3. Horowitz B: United States: solvent/detergent plasma; in AuBuchon JP, Prowse CV (eds): Patho-gen Inactivation: The Penultimate Paradigm Shift. Bethesda, AABB Press, 2010, pp 217-228.
4. Hellstern P, Sachse H, Schwinn H, Oberfrank K: Manufacture and in-vitro characterization of sol-vent/detergent-treated plasma. Vox Sang 1992;63: 178-185.
5. Horowitz B, Bonomo R, Prince AM, Chin SN, Brotman B, Shulman RW: Solvent/detergent-treat-ed plasma. A virus-inactivated substitute for fresh frozen plasma. Blood 1992;79:826-833.
6. Biesert L, Shartono H: Solvent/detergent treat-ment of human plasma-a very robust method for virus inactivation. Validation of virus safety of Octaplas. Vox Sang 1998;74(suppl 1):207-212. (Pubitemid 28379659)
7. Bonomo RJ: Removal of process chemicals from labile biological mixtures by hydrophobic interac-tion chromatography. US Patent 5.094.960. Wash-ington, DC, US Patent Office, 1992.
8. Pelletier JPR, Transue S, Snyder EL: Pathogen in-activation techniques. Best Pract Res Clin Haema-tol 2006;19:205-242.
9. Woods KR, Orme TW: Removal of lipid soluble process chemicals from biological materials by ex-traction with naturally occurring oils or synthetic substitutes thereof. US Patent 4.789.545, Washing-ton, DC, US Patent Office, 1988.
10. Solheim BG, Hellstern P: Pathogen inactivation of plasma and cryoprecipitate; in AuBuchon JP, Prowse CV (eds): Pathogen Inactivation: The Pe-nultimate Paradigm Shift. Bethesda, AABB Press, 2010, pp 69-98.
11. Andreu G: France: Solvent/detergent plasma; in AuBuchon JP, Prowse CV (eds): Pathogen Inacti-vation: The Penultimate Paradigm Shift Bethesda, AABB Press, 2010, pp 137-151.
12. Piquet Y, Janvier G, Selosse P, Doutremepuich C, Jouneau J, Nicolle G, Platel D, Vezon G: Virus in-activation of fresh frozen plasma by a solvent deter-gent procedure: biological results. Vox Sang 1992; 63:251-256.
13. Solheim BG, Cid J, Osselaer JC: Pathogen reduc-tion technologies; in Lozano M, Contreras M, Bla-jchman M (eds): Global perspectives in transfusion medicine. Bethesda, AABB Press, 2006, pp 103-148.
14. Horowitz B, Lazo A, Grossberg H, Page G, Lippin A, Swan G. Virus inactivation by solvent/detergent treatment and the manufacture of SD-plasma. Vox Sang 1998;74(suppl 1):203-206.
15. Heger A, Svae T-E, Neisser-Svae A, Jordan S, Be-hizad M, Römisch J: Biochemical quality of the pharmaceutical licensed plasma OctaplasLG after implementation of a novel prion protein (PrPSc) re-moval technology and reduction of the solvent/deter-gent (S/D) process time. Vox Sang 2009;97:219-225.
16. Burnouf T, Goubran HA, Radosevich M, Sayed MA, Gorgy G, El-Ekiaby M: A process for sol-vent/detergent treatment of plasma for transfusion at blood centers that use a disposable bag system. Transfusion 2006;46:2100-2108. (Pubitemid 44813727)
17. El-Ekiaby M, Radosevich M, Goubran H, El Sayed M, Burnouf T. New methods of plasma fractionation-a presentation of the 'mini-pool' fractiona-tion procedure developed in Egypt. ISBT Science Series 2009;4:99-106.
18. Horowitz B, Busch M: Estimating the pathogen safety of manufactured human plasma products: Application to fibrin sealants and to thrombin. Transfusion 2008;48:1739-1753.
19. Solheim BG, Rollag H, Svennevig JL, Arafa O, Fosse E, Bergerud U: Viral safety of solvent/deter-gent-treated plasma. Transfusion 2000;40:84-90.
20. Rollag H, Solheim BG, Svennevig JL: Viral safety of blood derivatives by immune neutralization. Vox Sang 1998;74(suppl 1):213-217. (Pubitemid 28379660)
21. Neisser-Svae A, Bailey A, Gregori L, Heger A, Jor-dan S, Behizad M, Reichl H, Römisch J, Svae TE: Prion removal effect of a specific affinity ligand in-troduced in the manufacturing process of the phar-maceutical quality solvent/detergent (S/D)-treated plasma OctaplasLG. Vox Sang 2009;97:226-233.
22. Svae TE, Neisser-Svae A, Bailey A, Reichl H, Biesert L, Schmidt T, Heger A, Römisch J: Prion safety of transfusion plasma and plasma-deriv-atives typically used for prophylactic treatment. Transfus Apher Sci 2008;39:59-67.
23. Sinnot P, Bodger S, Gupta A, Brophy M: Pres-ence of HLA antibodies in single-donor-derived fresh frozen plasma compared with pooled, solvent detergent-treated plasma (Octaplas®). Eur J Im-munogenet 2004;31:271-274. (Pubitemid 39572286)
24. Sachs UJH, Kauschat D, Bein G: White blood cell-reactive antibodies are undetectable in solvent/detergent plasma. Transfusion 2005;45:1628-1631.
25. Runkel S, Haubelt H, Hitzler W, Hellstern P: The quality of plasma collected by automated apher-esis and of recovered plasma from leukodepleted whole blood. Transfusion 2005;45:427-432. (Pubitemid 40389439)
26. Hellstern P: Solvent/detergent-treated plasma: composition, efficacy, and safety. Curr Opin He-matol 2004;11:346-350. (Pubitemid 40221052)
27. Solheim BG, Hellstern P: Composition, efficacy, and safety of S/D-treated plasma. Transfusion 2003; 43:1176-1178. (Pubitemid 37022383)
28. Heiden M, Salge U, Breitner-Ruddock S, Hum-feld A, Koenig H, Seitz R: Significant differences between S/D plasma qualities of different origin (abstract). Transfusion 2003; 43(suppl):56A.
29. Salge-Bartels U, Breitner-Ruddock S, Hunfeld A, Seitz R, Heiden M: Are quality differences respon-sible for different adverse reactions reported for SD-plasma for USA and Europe? Transfus Med 2006;16:266-275. (Pubitemid 44127878)
30. Burnouf T, Goubran HA, Radosevich M, Sayed MA, Gorgy G, El-Ekiaby M: Impact of Triton X-100 on alpha2-antiplasmin (SERPINF2) activity in solvent/detergent treated plasma. Biologicals 2007;35:349-353. (Pubitemid 47562783)
31. Murphy WG, Mikulich O: Ireland: Imported US-source solvent/detergent plasma; in AuBuchon JP, Prowse CV (eds): Pathogen Inactivation: The Pe-nultimate Paradigm Shift. Bethesda, AABB Press, 2010, pp 153-167.
32. Solheim BG, Svennevig JL, Mohr B, Dragsund M, Noddeland H, Töllefsrud S, Brosstad F, Rollag H, Mollnes TE: The use of Octaplas in patients under-going open heart surgery; in Müller-Berghaus G (ed): DIC: Pathogenesis, Diagnosis and Therapy of Disseminated Intravascular Fibrin Formation. Am-sterdam, Elsevier, 1993, pp 253-262.
33. Heim MU, Meyer B, Hellstern P: Recommenda-tions for the use of therapeutic plasma. Curr Vasc Pharmacol 2009;7:110-119.
34. Tølløfsrud S, Noddeland H, Svennevig JL, Bentsen G, Mollnes TE, Solheim BG: Universal fresh fro-zen plasma (Uniplas): a safe product on open-heart surgery. Intensive Care Med 2003;29:1736-1743. (Pubitemid 37373818)
35. Solheim BG, Granov DA, Juralv VA, Krawczyk M, Kubishkin VA, Patutko UI, Raab R: Universal fresh-frozen plasma (Uniplas): an explanatory study in adult patients undergoing elective liver re-section. Vox Sang 2005;89:19-26. (Pubitemid 40839546)
36. Scully M, Longair I, Flynn M, Berryman J, Machin SJ: Cryosupernatant and solvent detergent fresh-frozen plasma (Octaplas) usage in a single centre in acute thrombotic thrombocytopenic purpura. Vox Sang 2007;93:154-158. (Pubitemid 47228496)
37. Hellstern P: Fresh-frozen plasma, pathogen-reduced single-donor plasma or bio-pharmaceutical plas-ma? Transfus Apher Sci 2008;39:69-74.
38. Solheim BG, Flesland Ø: Norway: solvent/deter-gent plasma; in AuBuchon JP, Prowse CV (eds): Pathogen Inactivation: The Penultimate Paradigm Shift. Bethesda, AABB Press, 2010, pp 125-135.
39. Krusius T, Auvinen M-K, Tuimala: Introduction of Octaplas® in clinical use decreased the rate of seri-ous adverse reactions. Vox Sang 2010;99(suppl 1): P-1018.
40. Solheim BG, Bergan A, Brosstad F, Innes R, Sven-nevig JL: Fibrinolysis during liver transplant is en-hanced by using solvent/detergent virus inactivated plasma (ESDEP/Ocatplas®) (Letter) Anesth Analg 2003;96:1230-1231. (Pubitemid 36359074)